LGR5 and cancer: Intriguingly, Wnt inhibition in these cancers induces persisting differentiation and downregulation of CSC markers ASCL2 and LGR5. Similarly, OncoMed Pharmaceuticals reported anti-RSPO treatment of RSPO producing ovarian, colon, lung, and pancreatic cancers attenuated cancer growth and was again associated with reduced expression of CSC marker genes [42].